Another Disappointment With New Record Low While Psychedelic Drugs are experiencing increasing demand, HAVN Life Sciences continues to suffer from mismanagement and dreaded shortsellers as their stock has now reached a new record low.
Perhaps a very strong management shakeup similar to FSD Pharma is needed.